KOSDAQBiotech & Pharma199800

ToolGen Incorporated

₩34,500▼ 4.96%2026-10-02 close

Market Cap

₩310.9B

Turnover

₩1.2B

Volume

30,000 shares

Shares out.

PER

—

PBR

6.6×

EPS

-₩4,460

Dividend Yield

0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close

Report overview

Gene-Editing Pioneer at a Patent-Fight Crossroads

Revenue has grown yet losses have widened further, with the outcome of the US interference proceeding and parallel European and US patent suits emerging as the key variable for ToolGen's long-term value.

1
The only company to have independently developed ZFN, TALEN and CRISPR/Cas9, holding 388 patents, with technology licensing as its core revenue source.
2
2025 revenue rose to KRW 1.3 billion year over year, but the operating loss widened to KRW 23.3 billion, and the fourth-quarter net loss surged to KRW 22.5 billion.
3
After Broad Institute prevailed over the CVC group in their interference, the priority phase between ToolGen and Broad formally began in July 2026.
4
ToolGen expanded patent-infringement suits in the US, UK and Netherlands targeting Vertex's Casgevy production and sales network, while also successfully defending a plant patent in Europe.
5
The seed business has been refocused on drought- and herbicide-tolerant crops, and in May 2026 the company decided on a KRW 70 billion rights offering to fund litigation and R&D.

Business structure

ToolGen is Korea's first-generation gene-editing company, founded in 1999 by former Seoul National University professor Kim Jin-soo, which listed on KONEX in 2014 before moving to KOSDAQ in 2021.

The company is considered the only firm in the world to have independently developed first-generation ZFN, second-generation TALEN, and third-generation CRISPR/Cas9 gene-editing technologies.

Its business is structured around three pillars: licensing of source-patent technology, therapeutic pipeline development, and plant/seed gene editing.

Patent monetization through licensing of the gene-editing platform and technology transfer for therapeutics and seed development serves as the main revenue source, alongside ongoing expansion of global licensing based on CRISPR source patents and pipeline development in therapeutics and seeds.

In therapeutics, its gene-editing candidate TGT-001 targeting CMT1A (Charcot-Marie-Tooth disease type 1A) has received Orphan Drug Designation from the US FDA, and the company has also licensed out CRISPR gene-editing technology to Bioseed Research India, a unit of DCM Shriram.

The seed business division has recently undergone a fundamental restructuring, concentrating resources on a smaller set of pipelines with higher commercialization potential, namely drought tolerance (pepper, corn, soybean, canola) and herbicide tolerance (corn, soybean).

Competitively, the CVC group (UC Berkeley, University of Vienna, etc.) and the Broad Institute camp (MIT-Harvard) have already advanced to clinical and commercial stages through NASDAQ-listed spin-offs such as Intellia, Editas, and CRISPR Therapeutics, meaning that despite holding source patents, ToolGen is viewed as lagging in the pace of its own product commercialization.

Earnings trend

Quarterly revenue · Operating profit

₩100M-₩6.3B25Q2₩600M-₩5.4B25Q3₩400M-₩6.9B25Q4₩400M-₩4.6B26Q1₩500M-₩6.9B26Q2

RevenueOperating profit

Annual revenue · Operating profit

₩700M-₩19.4B2022₩1.1B-₩17.1B2023₩900M-₩21.8B2024₩1.3B-₩23.3B2025

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2025Q2	₩100M	-₩6.3B	−4439.8%
2025Q3	₩600M	-₩5.4B	−858.5%
2025Q4	₩400M	-₩6.9B	−1716.9%
2026Q1	₩400M	-₩4.6B	−1175.6%
2026Q2	₩500M	-₩6.9B	−1414.5%

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2022	₩700M	-₩19.4B	-₩18.2B	−2607.5%	−25.8%	7.0%
2023	₩1.1B	-₩17.1B	-₩42.3B	−1548.6%	−140.7%	210.5%
2024	₩900M	-₩21.8B	₩6.2B	−2446.6%	10.7%	29.2%
2025	₩1.3B	-₩23.3B	-₩36.8B	−1783.0%	−65.8%	10.4%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-21

Earnings analysis

Consolidated revenue fluctuated but remained very small in absolute terms: KRW 0.7 billion in 2022, KRW 1.1 billion in 2023, KRW 0.9 billion in 2024, and KRW 1.3 billion in 2025, with large quarter-to-quarter swings typical of lumpy licensing income recognition.

The operating loss steadily widened from KRW 19.4 billion in 2022 to KRW 17.1 billion in 2023, KRW 21.8 billion in 2024, and KRW 23.3 billion in 2025, reflecting rising R&D spending and mounting global patent-litigation costs.

Net income was far more erratic: after large losses of KRW -18.2 billion in 2022 and KRW -42.3 billion in 2023, the company turned to a net profit of KRW 6.2 billion in 2024 despite an ongoing operating loss of KRW -21.8 billion, before swinging back to a net loss of KRW -36.8 billion in 2025.

This pattern suggests a sizable gap between operating and net results driven by non-operating items.

On a quarterly basis, net losses attributable to owners were KRW -4.4 billion in 2025Q2, KRW -5.4 billion in Q3, and a notably enlarged KRW -22.5 billion in Q4, followed by KRW -4.4 billion in 2026Q1 and KRW -6.8 billion in Q2, with the fourth quarter of 2025 standing out as an outlier.

Over the most recent four quarters (2025Q3 through 2026Q2), the cumulative net loss attributable to owners reached about KRW 39.1 billion, confirming that the loss-making trend has persisted on an annualized basis as well.

Equity fell sharply from KRW 70.5 billion in 2022 to KRW 30.1 billion in 2023, recovered to KRW 58.4 billion in 2024, and edged down to KRW 55.9 billion in 2025, with these swings reflecting both net income/loss and capital-raising activity.

The debt ratio spiked from 7.0% in 2022 to 210.5% in 2023 before falling back to 29.2% in 2024 and 10.4% in 2025.

Operating cash flow was negative in every year shown (KRW -15.0 billion in 2022, -14.9 billion in 2023, -16.5 billion in 2024, and -20.2 billion in 2025), underscoring a structure in which the core business does not generate cash and the company continues to depend on external financing.

Industry analysis

The global gene-editing market is expanding rapidly as CRISPR-based therapies reach commercialization, and the three-way source-patent dispute among ToolGen, Broad Institute, and the CVC group has become a key variable shaping royalty structures across the industry.

The CVC group and the Broad Institute camp each established spin-off companies such as Intellia, Editas, and CRISPR Therapeutics and listed them on NASDAQ, raising substantial capital.

CRISPR Therapeutics partnered with Vertex to commercialize the world's first CRISPR-based gene-editing therapy, Casgevy, in 2023, securing an early market position.

While these companies have steadily delivered clinical progress across agricultural applications and next-generation cell therapies such as CAR-T, ToolGen has been seen as comparatively slower both in actively leveraging its intellectual property and in building out its own commercial business.

The patent landscape has shifted notably in recent months: a Chinese patent court's first-instance ruling declined to recognize the CVC group's priority invention claim at the eukaryotic-cell stage, indirectly affirming ToolGen's position as the earlier filer, while in the US, Broad Institute's win over the CVC group in their interference cleared the way for the long-dormant second-stage, priority-phase interference between ToolGen and Broad to resume.

In Europe, a CRISPR RNP-based plant gene-editing patent (EP3346003) was upheld after the opposition division reversed its preliminary decision at oral hearing, a contrasting outcome to Broad- and CVC-affiliated patents that were voluntarily withdrawn in similar proceedings.

Competitively, ToolGen's rare breadth of source technology, having independently developed every generation of ZFN, TALEN, and CRISPR/Cas9, stands in contrast with a broader market view that the company still lags globally listed and clinically advanced competitors in the pace of actual product commercialization and revenue generation.

Outlook

CEO Yoo Jong-sang stated in a New Year interview that "2026 will be the year ToolGen's world-class technology translates into real financial results," signaling strong intent to monetize its IP.

The company was granted Senior Party status in the motion phase of the US interference proceeding in September 2022, and after Broad Institute prevailed over the CVC group in their interference in March 2026, the priority-phase interference between ToolGen and Broad formally began in July 2026.

The company has also been pursuing offensive litigation, filing patent-infringement suits in the Netherlands in September 2025 against Vertex's contract manufacturer Lonza, and in the US in November 2025 against Vertex based on a newly registered RNP patent, following a similar suit filed in the UK in April 2025.

The seed business division has narrowed its pipeline to crops with higher commercialization potential, and regarding pepper-related negotiations the CEO noted that "negotiations for pepper technology transfer have progressed considerably,

Valuation

PER

—

PBR

6.6×

ROE

-77.4%

EPS

-₩4,460

BPS

₩5,370

Dividend per share

₩0

ToolGen has continued to post losses in most recent years without a clear sustained turn to profit, aside from a temporary net profit in 2024, placing it in a range where conventional earnings-based valuation metrics are difficult to apply.

Its price-to-book ratio tends to trade at a level reflecting a substantial premium over net asset value, suggesting that market pricing reflects expectations tied to the source-patent portfolio and the outcome of the interference and litigation proceedings more than realized earnings.

On dividends, the company has not paid a dividend in recent years, consistent with a structure that prioritizes funding for R&D and patent defense over shareholder returns.

In the past, during its early KOSDAQ relisting period and when gene-editing technology drew attention following a Nobel Prize award, market capitalization expanded considerably, but subsequent delays in patent litigation and commercialization have led the valuation band itself to be repeatedly reset over time.

How the ongoing US interference proceeding and the European and US patent suits are ultimately resolved could significantly change the yardstick by which the market evaluates the company going forward.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-21

Bull factors

The world's only source-patent portfolio spanning every gene-editing generation

ToolGen is the only company to have independently developed ZFN, TALEN, and CRISPR/Cas9, holding 388 patents, a rare asset in an industry with high barriers to entry.

It holds Senior Party status in the US interference proceeding, a procedurally favorable position, and has continued expanding its patent portfolio, including adding three newly registered CRISPR RNP patents to its litigation.

Recent favorable rulings in China and Europe are cited as evidence supporting the substantive value of its source patents.

Resumed interference proceeding and multi-front patent offensive

After Broad Institute won its interference against the CVC group, the long-dormant priority-phase interference between ToolGen and Broad formally began in July 2026.

Separately, the company has expanded patent-infringement suits in the US, UK, and Netherlands against entities involved in producing and selling Vertex's Casgevy, and has also successfully defended a plant patent in Europe.

This structure leaves open the possibility of monetization through licensing or settlement depending on litigation outcomes.

Revenue diversification and pipeline restructuring

In therapeutics, TGT-001 targeting CMT1A has received US FDA Orphan Drug Designation, and the seed business has been restructured around drought- and herbicide-tolerant crops, with negotiations for certain crops including pepper reported to have progressed considerably.

A technology license to Bioseed Research India in India also exists, maintaining a business model that extends source patents across multiple industries including therapeutics and agriculture.

Bear factors

Persistent large losses and reliance on external financing

The operating loss widened steadily from KRW 19.4 billion in 2022 to KRW 23.3 billion in 2025, and operating cash flow was negative in every year shown, meaning the core business does not generate cash.

Net losses also swung sharply, surging to KRW 22.5 billion in the fourth quarter of 2025 alone, reflecting significant non-operating volatility. This structure could continue to necessitate reliance on external financing such as rights offerings going forward.

Uncertainty over patent litigation outcomes

Senior Party status does not guarantee an eventual win, and it has repeatedly been noted that both the interference proceeding and the European and US lawsuits could take a long time to resolve.

There have been instances of reversed rulings by jurisdiction, such as in Australia where a patent registration was once cancelled before later being upheld by a court, making outcomes difficult to predict. The longer litigation continues, the more cost burden could accumulate.

Lagging pace of commercialization relative to competitors

The CVC group and Broad Institute camp have already reached clinical and commercial stages through NASDAQ-listed companies such as Intellia, Editas, and CRISPR Therapeutics, and commercialized the world's first CRISPR therapy with Vertex in 2023.

By contrast, ToolGen has been assessed as having been comparatively slower both in actively leveraging its IP and in building out its own commercial business. Its seed business is also understood to have had limited success converting its broader pipeline into actual commercialization.

Risk factors

Litigation and patent risk

The priority-phase outcome of the US interference has not yet been determined, and multiple ongoing lawsuits in Europe, the US, the Netherlands, and the UK also remain unresolved. An unfavorable ruling could impair the commercial value of the source patents themselves. Prolonged litigation would also mean accumulating legal cost burdens.

Financing and dilution risk

Given a structure of negative operating cash flow every year, continued reliance on external financing appears unavoidable, and the rights offering decided in May 2026 is one such example.

According to media reports the actual amount raised was reduced from the plan due to a decline in the share price, and the possibility of needing additional financing in the future cannot be ruled out. Repeated rights offerings could lead to dilution for existing shareholders.

Commercialization delay risk

The company has stated it aims to sign technology-transfer deals for certain seed crops such as pepper within the year, but negotiations always carry the possibility of delay or breakdown before a deal is finalized.

The therapeutic pipeline also requires a separate, lengthy path from orphan drug designation to clinical development and commercialization. As seen in the company's multiple past setbacks in its KOSDAQ relisting attempts, procedural delay has been noted as a recurring characteristic.

What to watch next

Mid-November 2026
Timing of the 2026 third-quarter (July-September) earnings disclosure, when the scale of recognized revenue and any non-operating drivers of net income should be checked.
Q4 2026 through H1 2027
Monitoring the progress of the US PTAB priority-phase interference hearing and any further procedural rulings.
Q4 2026
A point to check whether the seed business division's stated goal of signing a technology-transfer deal for crops such as pepper within the year is met.
Q4 2026
Need to check hearing schedules and any further rulings or settlement discussions in the Netherlands (Lonza) and UK/US (Vertex) patent lawsuits.
Q4 2026
Need to review how closely the final amount raised and the use of proceeds from the May 2026 rights offering align with the original plan.

Overall view

ToolGen holds the rare asset of being the world's only company to have independently developed ZFN, TALEN, and CRISPR/Cas9, yet it continues to struggle to convert this into actual revenue and stable profit.

While 2025 revenue rose year over year, the operating loss actually widened to KRW 23.3 billion, and the fourth-quarter net loss surged to KRW 22.5 billion, reflecting relatively low earnings predictability.

Operating cash flow was negative for four consecutive years, sustaining a structure dependent on external financing, and the KRW 70 billion rights offering decided in May 2026 emerged in this context.

The company's core value appears likely to hinge heavily on the outcome of the priority-phase interference in the US and the numerous ongoing patent lawsuits in Europe and the US, with the formal start of the hearing against Broad Institute in July 2026 marking an important milestone.

Progress in seed-business technology-transfer negotiations and the therapeutic pipeline also remain variables that will shape future earnings visibility.

Investors should weigh the procedural progress of the patent litigation, the non-operating drivers behind quarterly results, and the possibility of further capital raises in a balanced way.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-09-05 · Data as of 2026-09-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.